Antibody Therapeutics for Life

History

  • 2018
    • 1.16
    • Collaboration Agreement of TTAC-0001 in
      Combination Therapy with Keytruda of MSD
    • 3.8
    • FDA Orphan Drug Designation Granted to TTAC-0001
  • 2017
    • 4.13
    • 2017 Korea Health Industry Development
      Institute Award
    • 6.
    • TTAC-0001 Clinical Phase IIa terminated
    • 9.9
    • Designated as K-Brain Power 2017
  • 2016
    • 2.10
    • TTAC-0001 phase IIa FIH(Australia)
    • 6.27
    • Ministry of Food & Drug Safety Award
  • 2015
    • 10.15
    • TTAC-0001-Excellence in national R&D
      Selected for 100 selections (best accomplishments)
      and Ministry of Science and ICT Award
  • 2014
    • 3.4
    • Selected as INNOBIZ Company
    • 3.11
    • TTAC-0001 license-out to Eye disease
    • 5.26
    • Korea Eureka Day Award 2014
    • 6.25
    • TechConnect National Innovation Award
    • 7.16
    • PMC-001 license-out
    • 10.29
    • TTAC-0001 license-out
    • 11.13
    • Commendation of Ministry
      of Trade, Industry & Energy
      (Dr. Jin-San Yoo &
      Dr. Sung-Woo Kim)
    • 12.17
    • Health & Medical Technology
      Development Merit Award
      (Yoo, Jin San)
    • 12.25
    • PMC-001 license-out
  • 2013
    • 3.22
    • 1E4 antibody license-out to local pharma
    • 9.25
    • TTAC-0001 Clinical Phase 1 terminated
    • 10.23
    • Ministry of Education Award
  • 2012
    • 4.25
    • Won the Pharma Idol Award from the 7th Annual
      China Pharmaceutical R&D Summit Conference
    • 11.1
    • Joint research agreement with Sanofil-Aventis
      for anticancer agent
  • 2011
    • 7.25
    • Korean FDA IND approval for TTAC-0001
    • 9.23
    • Green Technology Certification
    • 11.8
    • TTAC-0001 phase I FIH(Korea)
  • 2009
    • 3.13
    • Certified as venture business
    • 9.22
    • Designated as foreigner investment company
    • 12.17
    • Affiliated R&D center installed
  • 2008
    • 9.3
    • PharmAbcine Inc. established
    • 10.9
    • The 1st GATE Project Award